Galen sticking to its principles as it embarks on ambitious future

galen-dennise-broderick-large

Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes.

As chief executive of the privately-owned global pharmaceutical sales and marketing company, Dennise has played a pivotal role in Galen’s growing success over the past 5 years. Under her guidance, the company has expanded into new territories and therapeutic areas, building on its previous successes.

To dig deeper into Galen’s success, you must first look at its leader’s own experiences in the industry. Starting out in academia and sales, she has been mentored and nurtured into a leader herself. Now, she pays it back by mentoring others, demonstrating that even in top positions, one can remain grounded and committed to supporting others.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical